Predictive Oncology Launches New AI Platform for Vaccine and Drug Development Targeting Coronaviruses and Acute Respiratory Syndromes
With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms to Aid in Vaccine and Drug Development
Predictive Oncology Inc., a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announces it will launch a new AI platform for vaccine and drug development targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS) through an operating agreement with Soluble Therapeutics. POAI has also signed a letter of intent with InventaBioTech to acquire Soluble Therapeutics, its assets and its HSC Technology.
Global health experts are predicting an ever-increasing number of viral outbreaks like COVID-19, POAI is taking proactive measures to be part of the solution by applying artificial intelligence to aid in the development of new drugs and vaccines. Utilizing Soluble Therapeutics’ HSC technology and its six machines, Soluble’s computer system expects to be able to run over 12,000 computer simulations per machine to help generate new diagnostics, vaccines and therapeutics. Soluble’s HSC technology has demonstrated efficacy with both new and existing vaccine and drug programs, ensuring the best delivery mechanisms to address new pandemics and battle cancers.
The market for biologicals that includes vaccines, proteins and antibodies used in disease treatment is projected to reach $479.7 billion by 2024 at a compound annual growth rate (CAGR) of 10.9%.* The capital the US Congress has allocated to fight COVID-19 is $8.0 billion dollars.
Protein formulation is often a bottleneck in protein-based drug development, and Soluble Therapeutics’ technology directly addresses this bottleneck. Combining the HSCTM technology with POAI’s predictive modeling platform is expected to create a new rapid AI discovery platform that quickly and cost-effectively identifies potential therapeutic candidates. The HSCTM technology accelerates the formulation process and is believed to achieve in a month what can take a team of scientists several months to a year to achieve. The HSCTM technology only requires milligrams where a traditional formulation effort can require up to a gram of material.
Recommended AI News: Wilson Elser Announces Global Cyber Capabilities
HSC™ Technology is a self-contained, automated, chromatographic system that conducts high throughput, microcapillary, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations. The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination(s) of additives and excipients, resulting in increased solubility and physical stability of proteins. The system works in concert with a predictive algorithm of formulation parameters that can be exclusively accessed through Soluble Therapeutics.
The HSC™ Instrument, and underlying technology, has been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients and vaccine manufacturers, this means faster development times and quicker progression of molecules into the clinic. The COVID-19 vaccine development efforts by industry and government can benefit enormously using the Soluble HSCTM technology with POAI’s predictive modeling platform.
Recommended AI News: Amazon Go Grocery Opens Largest Contactless Retail Store in Seattle
“Soluble has six customized machines in its facilities that can help identify the best solutions for vaccines, proteins or antibodies being developed to help fight the COVID-19 contagion. Through this operating partnership and acquisition, we are ready to assist in the development of viable treatment options that use biological, complex ingredients and formulations to speed up the pre-clinical and clinical development of treatments’, said Carl Schwartz, CEO of Predictive Oncology.
“The combination of Soluble Therapeutics’ technology with Predictive Oncology’s AI capability has the potential to rapidly optimize formulations thereby accelerating the early phase of protein therapeutic development”, said Dr. Larry DeLucas, co-inventor of the HSC technology.
Under the operating agreement, the Company and existing Soluble managers will operate the Soluble Therapeutics business pending the acquisition. The Company’s acquisition of Soluble Therapeutics is subject to the completion of a definitive agreement and customary closing conditions and is expected to close in the second quarter of 2020.
Recommended AI News: Omnichannel Payments App BharatPe Scoops $75 Million In Series C Funding
Comments are closed, but trackbacks and pingbacks are open.